您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > NVP-TNKS656
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
NVP-TNKS656
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
NVP-TNKS656图片
包装与价格:
包装价格(元)
2mg电议
5mg电议
25mg电议

产品介绍
NVP-TNKS656 是一种高效、选择性和口服活性的 TNKS2 抑制剂,IC50 为 6 nM,对 PARP1 和 PARP2 的选择性是 >300 倍。

Animal experiment:

Athymic female nude mice weighing 19-22 g are implanted subcutaneously with a 3×3×3 mm3 tumor fragment from an MMTV-Wnt1 tumor-bearing mouse. Tumors are grown to approximately 250-300 mm3. Individual mice are given a single oral dose of vehicle (n=3) (4% HCl:10% propylene glycol:20% Solutol HS15:60.5% D5W:0.5% NaOH) or TNKS656 at 350 mg/kg (n=18). At 0.5, 1, 2, 4, 8, 16, or 24 h following dosing (n=3/time point), mice are euthanized, and blood is collected via cardiac puncture and processed for plasma. Tumors are excised from mice and frozen at –80℃ for PD analysis.

产品描述

NVP-TNKS656 is an orally active antagonist of Wnt pathway activity. The Wnt pathway has been involved in controlling numerous developmental processes. Dysfunction of this pathway may result in carcinogenesis [1].

In vitro: The IC50 value of NVP-TNKS656 against PARP1, TNKS2, PARP2, and STF was >19, 0.006, 32, and 0.0035 μM, respectively [1].

In vivo: The clearance and volume of distribution of NVP-TNKS656 were 10 mL/min/kg and 0.6 L/kg after intravenous administration in mice. The exposure and oral bioavailability was 32% and 53%, respectively. In the mouse mammary tumor virus (MMTV)-Wnt1 transgenic model, oral administration of NVP-TNKS656 (350 mg/kg) activated the Wnt signaling over a 24-h time course. NVP-TNKS656 treatment reduced the Wnt/beta-catenintarget gene Axin2 mRNA level by 70-80% [1].

Reference:
Shultz M D, Cheung A K, Kirby C A, et al.  Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor[J]. Journal of medicinal chemistry, 2013, 56(16): 6495-6511.